How this company measures up on the fundamentals that matter
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies; gene therapy with InspiroGene, practice consulting, and vaccine distribution services; and technology solutions, as well as research, insights, technologies, and services to improve cancer and specialty care. In addition, the company helps in solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Further, it offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, dispensing support services, patient enrollment, third-party logistics, and wholesale distribution support; medical-surgical supplies, laboratory equipment, pharmaceutical distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, and hospital reference labs, nursing homes, hospice and home health care agencies, government facilities ,and online marketplaces and retailers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Trading at $760, 26% above fair value of $604. Passes all ethical screens. Ranks better than 56% of screened stocks.
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Trading characteristics and market positioning
Balance sheet strength and cash generation — the foundation of long-term value
SEC Form 4 filings — what company insiders are buying and selling
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-19 | VITALONE BRITT J | Chief Financial Officer | 8,979 | — | |
| 2026-05-19 | RODGERS THOMAS L | Officer | 3,614 | — | |
| 2026-05-19 | RUTLEDGE NAPOLEON B JR | Officer | 788 | — | |
| 2026-05-19 | LAU MICHELE | Officer | 4,454 | — | |
| 2026-05-19 | SMITH LEANN B | Officer | 4,129 | — | |
| 2026-05-19 | FRAGA FRANCISCO | Chief Technology Officer | 3,127 | — | |
| 2026-03-02 | LAU MICHELE | Officer | 2,725 | $2,697,750 | |
| 2026-02-19 | MARTINEZ MARIA N. | Director | 349 | $328,013 | |
| 2026-02-17 | SMITH LEANN B | Officer | 190 | $179,550 | |
| 2026-02-11 | LAU MICHELE | Officer | 303 | $282,817 |
Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15